Literature DB >> 28509380

Amyloid is essential but insufficient for Alzheimer causation: addition of subcellular cofactors is required for dementia.

Jeffrey Fessel1.   

Abstract

OBJECTIVE: The aim of this study is to examine the hypotheses stating the importance of amyloid or of its oligomers in the pathogenesis of Alzheimer's disease (AD).
METHODS: Published studies were examined.
RESULTS: The importance of amyloid in the pathogenesis of AD is well established, yet accepting it as the main cause for AD is problematic, because amyloid-centric treatments have provided no clinical benefit and about one-third of cognitively normal, older persons have cerebral amyloid plaques. Also problematic is the alternative hypothesis that, instead of amyloid plaques, it is oligomers of amyloid precursor protein that cause AD.Evidence is presented suggesting amyloid/oligomers as necessary but insufficient causes of the dementia and that, for dementia to develop, requires the addition of cofactors known to be associated with AD. Those cofactors include several subcellular processes: mitochondrial impairments; the Wnt signaling system; the unfolded protein response; the ubiquitin proteasome system; the Notch signaling system; and tau, calcium, and oxidative damage.
CONCLUSIONS: A modified amyloid/oligomer hypothesis for the pathogenesis of AD is that activation of one or more of the aforementioned cofactors creates a burden of functional impairments that, in conjunction with amyloid/oligomers, now crosses a threshold of dysfunction that results in clinical dementia. Of considerable importance, several treatments that might reverse the activation of some of the subcellular processes are available, for example, lithium, pioglitazone, erythropoietin, and prazosin; they should be given in combination in a clinical trial to test their safety and efficacy. © 2017 John Wiley & Sons, Ltd.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  amyloid; erythropoietin; lithium; modification; pioglitazone; subcellular processes

Mesh:

Substances:

Year:  2017        PMID: 28509380     DOI: 10.1002/gps.4730

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  6 in total

1.  Human Herpesvirus 6 Detection in Alzheimer's Disease Cases and Controls across Multiple Cohorts.

Authors:  Mary Alice Allnutt; Kory Johnson; David A Bennett; Sarah M Connor; Juan C Troncoso; Olga Pletnikova; Marilyn S Albert; Susan M Resnick; Sonja W Scholz; Philip L De Jager; Steven Jacobson
Journal:  Neuron       Date:  2020-01-23       Impact factor: 17.173

2.  PET imaging of tau protein targets: a methodology perspective.

Authors:  Cristina Lois; Ivan Gonzalez; Keith A Johnson; Julie C Price
Journal:  Brain Imaging Behav       Date:  2019-04       Impact factor: 3.978

Review 3.  Prevention of Alzheimer's disease by treating mild cognitive impairment with combinations chosen from eight available drugs.

Authors:  Jeffrey Fessel
Journal:  Alzheimers Dement (N Y)       Date:  2019-11-16

Review 4.  EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease.

Authors:  Vladimir Khavinson; Natalia Linkova; Ekaterina Kozhevnikova; Svetlana Trofimova
Journal:  Molecules       Date:  2020-12-31       Impact factor: 4.411

5.  Reversing Alzheimer's disease dementia with clemastine, fingolimod, or rolipram, plus anti-amyloid therapy.

Authors:  Jeffrey Fessel
Journal:  Alzheimers Dement (N Y)       Date:  2022-02-01

Review 6.  Biomarkers: Our Path Towards a Cure for Alzheimer Disease.

Authors:  Rawan Tarawneh
Journal:  Biomark Insights       Date:  2020-11-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.